> After failing at raising new money to mount a clinical trial on its bird flu therapy, Irving, TX-based DelSite filed plans last week to liquidate the company. The company had been working on a flu therapy that formed into a jelly after being sprayed into the nose. Release
> Seattle-based Cell Therapeutics has snared a $6.5 million payment from Spectrum Pharmaceuticals related to the sale of its stake in Zevalin. Story
> Seattle Genetics will pick up a $4 million upfront fee after inking a deal with Millennium: the Takeda Oncology, a wholly owned subsidiary of Takeda Pharmaceutical, for the development of antibody-drug conjugates. Release
> What haunts Lilly CEO John Lechleiter's work anxiety dreams? Year Y and Year Z. They're the continuation of a series that began in 2001, a.k.a. Year X, when the blockbuster antidepressant Prozac went off patent. Report
> Lately, FDA has cited a series of drugmakers for online video that didn't weigh in heavily enough on the side effects and risks of drugs. And now, the agency is cracking down on search engine ads. Report
> Remember Merck CEO Dick Clark's talk about pharma's "trust deficit?" The drugmaker's chief dusted off last year's phrase for PhRMA's annual meeting, aiming to remind the industry that sales depend on regaining America's trust. Report
> If the FDA panel approves AstraZeneca's extended release Seroquel as a treatment for depression and generalized anxiety disorder, the drug will be one step closer to an enormous expansion of its potential market. Report
> Few drugmakers are expected to have a year as tough as Bristol-Myers Squibb's 2012. Like the Mayan calendar, time would run out in 2012 on two of Bristol's blockbuster meds: Plavix and Abilify. And voila! Some $7.8 billion in sales threatened. Report
And Finally... Mice born without a certain enzyme can resist the normal effects of a heart attack and retain nearly normal function in the heart's ventricles and still-oxygenated heart tissue, according to a study by researchers at Duke University Medical Center. Release